1-9 of 9
Michail S. Lionakis
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib in Teddi-R with Isavuconazole for Relapsed and Refractory Primary DLBCL of the CNS

Mark Roschewski, Christopher Melani, Rahul Lakhotia, Tatyana Gavrilova, Jagan R. Muppidi, James D. Phelan, Michail S. Lionakis, Kieron Dunleavy, Lode J. Swinnen, Matthias Holdhoff, Catherine E. Lai, Sami Ibrahimi, Michael Glantz, Jan Drappatz, John A. Butman, Stefania Pittaluga, Kim Johnson, Candis Morrison, Nick Micheletti, John D. Heiss, William D. Figg, Elaine S. Jaffe, S. Percy Ivy, Richard Little, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2024) 144 (Supplement 1): 3122.
https://doi.org/10.1182/blood-2024-199168
Published: 2024
Journal Articles

Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib

Mark Roschewski, James D. Phelan, Stefania Pittaluga, Christopher Melani, Rahul Lakhotia, Jacob J. Chabon, Jagan R. Muppidi, Kathryn A. Lurain, Jillian Simard, Amynah Pradhan, Amy Hillsman, Madeline Rilko, Seth M. Steinberg, George W. Wright, Da Wei Huang, Yandan Yang, Michail S. Lionakis, Alexander Bagaev, Ekaterina Postovalova, Mark Meerson, Olga Kudryashova, Nikita Kotlov, Nathan H. Fowler, David M. Kurtz, Ash A. Alizadeh, Elaine S. Jaffe, Louis M. Staudt, Wyndham H. Wilson
Journal: Blood
Blood (2021) 138 (Supplement 1): 524.
https://doi.org/10.1182/blood-2021-145228
Published: 2021
Journal Articles

Phase 1 Study of Escalating Doses of Ibrutinib and Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) with Isavuconazole for Relapsed and Refractory Primary CNS Lymphoma

Mark Roschewski, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Cody Peer, PhD, Michail S. Lionakis, MD ScD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, Jan Drappatz, MD, Catherine Lai, MD MPH, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, William D. Figg, PhD, Elaine S. Jaffe, MD, S. Percy Ivy, MD, Richard F. Little, MDMPH, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 12–13.
https://doi.org/10.1182/blood-2020-137637
Published: 2020
Journal Articles

Preliminary Results of a Response-Adapted Study of Ibrutinib and Isavuconazole with Temozolomide, Etoposide, Liposomal Doxorubicin, Dexamethasone, Rituximab (TEDDI-R) for Secondary CNS Lymphoma

Jillian Simard, MD, Christopher Melani, MD, Rahul Lakhotia, MD, Michail S. Lionakis, MD ScD, Stefania Pittaluga, MD PhD, James D. Phelan, PhD, Jagan R. Muppidi, MD PhD, Lydia L. Chou, CRNP, Matthias Holdhoff, MD PhD, Michael Glantz, MD PhD, John A. Butman, MD PhD, Andrea Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, MD, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD, Mark Roschewski, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 24–25.
https://doi.org/10.1182/blood-2020-137709
Published: 2020
Journal Articles

Fulminant pneumococcal sepsis due to APECED-associated autoimmune asplenia

Monica M. Schmitt, Michail S. Lionakis
Journal: Blood
Blood (2020) 135 (4): 298.
https://doi.org/10.1182/blood.2019003900
Published: 2020
Journal Articles

Reponse-Adapted Study of Ibrutinib with Temozolomide, Etoposide, Doxil, Dexamethasone, and Rituximab (TEDDI-R) in Aggressive B-Cell Lymphomas with Secondary Involvement of the CNS

Mark Roschewski, MD, Christopher Melani, MD, Kieron Dunleavy, MD, Matthias Holdhoff, MD PhD, Lode J. Swinnen, MB ChB, Michael Glantz, MD PhD, Craig A. Portell, MD, Jakub Svoboda, MD, Rafic Farah, MD, Michail S. Lionakis, MD ScD, Louis Staudt, MD, Wyndham Wilson, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2875.
https://doi.org/10.1182/blood-2019-123552
Published: 2019
Journal Articles

Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects

Amy P. Hsu, Agnes Donkó, Megan E. Arrington, Muthulekha Swamydas, Danielle Fink, Arundhoti Das, Omar Escobedo, Vincent Bonagura, Paul Szabolcs, Harry N. Steinberg, Jenna Bergerson, Amanda Skoskiewicz, Melanie Makhija, Joie Davis, Ladan Foruraghi, Cindy Palmer, Ramsay L. Fuleihan, Joseph A. Church, Avinash Bhandoola, Michail S. Lionakis, Sharon Campbell, Thomas L. Leto, Douglas B. Kuhns, Steven M. Holland
Journal: Blood
Blood (2019) 133 (18): 1977–1988.
https://doi.org/10.1182/blood-2018-11-886028
Published: 2019
Includes: Multimedia, Supplemental data
Journal Articles

Dose-Adjusted Teddi-R Induces Durable Complete Remissions in Relapsed and Refractory Primary CNS Lymphoma

Mark Roschewski, MD, Michail S. Lionakis, MD ScD, Christopher Melani, MD, John A. Butman, MD PhD, Stefania Pittaluga, MD PhD, A. Nicole Lucas, RN, Seth M. Steinberg, PhD, Elaine S. Jaffe, Richard F. Little, MD MPH, Louis M. Staudt, MD PhD, Wyndham H. Wilson, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 4195.
https://doi.org/10.1182/blood-2018-99-112184
Published: 2018
Journal Articles

CARD9: at the intersection of mucosal and systemic antifungal immunity

Michail S. Lionakis, Steven M. Holland
Journal: Blood
Blood (2013) 121 (13): 2377–2378.
https://doi.org/10.1182/blood-2013-01-480434
Published: 2013